

## **MEDIA ADVISORY**

### **Limerick NeuroSciences to Present at BIO Investor Forum 2007**

South San Francisco, Calif. – October 4, 2007 – Limerick NeuroSciences, Inc., a privately held biopharmaceutical company, will present a corporate overview at the Biotechnology Industry Organization's 4<sup>th</sup> Annual BIO Investor Forum being held in San Francisco from October 9 – 11, 2007. Wendye R. Robbins, M.D., Limerick President and Chief Executive Officer, will speak on Wednesday, October 10 at 10:00 a.m. PT.

Limerick NeuroSciences ([www.limerickneuro.com](http://www.limerickneuro.com)) is a venture-funded biopharmaceutical company focused on the development of safe and potent pharmaceuticals with attenuated neurotoxicity. The company has identified a proprietary means of improving existing therapeutics by chemically modulating bioavailability. Limerick's first clinical compound, LNS 5310, is an efflux transport activator that is being studied in a Phase I trial for safety, tolerability and pharmacokinetics when co-administered with an opiate to treat pain. Results from this trial are expected later this year.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. Registration to the Investor Forum is complimentary for credentialed members of the media. For more information and to register, visit <http://investorforum.bio.org/opencms/bif/2007/>.

**Limerick**      Debra Bannister  
**Media**        530 676-8001  
**Contact:**    [pr@limerickneuro.com](mailto:pr@limerickneuro.com)